Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective

Pitoia, Fabián; Scheffel, Rafael Selbach; Califano, Inés; Gauna, Alicia; Tala, Hernán; Vaisman, Fernanda; Román-Gonzaléz, Alejandro; Hoff, Ana O.; Maia, Ana Luiza

doi:10.1007/s11154-023-09818-0

Cited by 4 publications

(1 citation statement)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In RAI-R disease, tumors become resistant and can no longer receive this treatment. Even some differentiated thyroid carcinomas (DTC) that become RAI-R are mainly due to the upregulation of TRK that can support cancer growth [37]. Fazeli et al [39] identify NTRK fusion in advanced and RAIrefractory disease.…”

Section: Radioactive Iodine (Rai)-refractory Disease and Papillary Th...mentioning

confidence: 99%

NTRK-fusion detection in thyroid and salivary gland cancer offers a targeted therapy with NTRK-inhibitor

Hana Evangelin Prayogo,

Willy Sandhika

2023

GSC Biol. Pharm. Sci.

View full text Add to dashboard Cite

NTRK-fusion in cancer is rare but it offers targeted therapy with NTRK-inhibitor. NTRK fusion is not a point mutation. NTRK fusion is an oncogenic driver, NTRK mutation is not an oncogenic driver. Patients with NTRK point mutation do not respond to NTRK-targeted therapy. NTRK fusion was detected in secretory carcinoma. Secretory carcinoma was a new entity, first described in 2010, classified by NTRK-fusion. It is often misdiagnosed, and standard pathology often fails to distinguish it from another histology subtype of salivary gland carcinoma, so its frequency can be higher than has been reported. Therefore, different examinations are needed in order to obtain a correct diagnosis. In thyroid gland carcinoma, NTRK fusion-positive carcinomas are associated with clinically aggressive disease with a high metastatic rate. Therefore NTRK-fusion test should be performed in thyroid cancer patients with recurrence and unresectable disease, metastatic thyroid cancer, Radioactive Iodine (RAI)-refractory disease, and invasive disease. Immunohistochemistry with antibody against TRKA, TRKB, and TRKC can be used to identify TRK protein expression in salivary gland cancer so this test can be used for screening in all salivary gland cancers. NGS or FISH are tools that can be used to confirm NTRK fusion. Detection of NTRK fusion allows new hope for cancer patients with refractory therapy.

show abstract

Section: Radioactive Iodine (Rai)-refractory Disease and Papillary Th...mentioning

confidence: 99%

NTRK-fusion detection in thyroid and salivary gland cancer offers a targeted therapy with NTRK-inhibitor

Hana Evangelin Prayogo,

Willy Sandhika

2023

GSC Biol. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease

Califano,

Smulever,

Jerkovich

et al. 2023

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Ten years’ real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer

Jerkovich,

Capalbo,

Abelleira

et al. 2024

Endocrine

Self Cite

View full text Add to dashboard Cite

To evaluate objective response rates (ORR), progression-free survival (PFS), and overall survival (OS) associated with tyrosine kinase inhibitors (TKIs) in patients with radioiodine refractory differentiated thyroid cancer (RR-DTC). Additionally, to compare: i) ORR and PFS among patients treated with lenvatinib and sorafenib; ii) ORR and PFS among patients receiving lenvatinib as rst-line vs. second-line and; iii) adverse effects (AEs) observed in patients treated with these medications. MethodsRetrospective analysis of RR-DTC adult patients treated with TKIs at the Division of Endocrinology, University of Buenos Aires (March 2011-November 2023). ResultsAmong 43 patients included in the study, 32 received sorafenib (30 as rst-line and 2 as second-line), while 29 received lenvatinib (12 as rst-line and 17 as second-line). The median PFS and OS for the entire cohort were 32.7 and 39.0 months, respectively. Lenvatinib demonstrated a signi cantly higher ORR compared to sorafenib (37.9% vs. 9.4%, p = 0.008). However, both drugs exhibited similar median PFS (23.2 vs. 16.0 months, p = 0.419). No signi cant difference was observed in ORR and PFS between patients receiving rst-line vs. second-line lenvatinib. Sorafenib-treated patients experienced higher rates of hand-foot skin syndrome (69% vs. 41%, p = 0.032) and alopecia (25% vs. 3%, p = 0.018), whereas lenvatinib-treated patients had higher rates of proteinuria (31% vs. 0%, p < 0.001) and grade 3 hypertension (31% vs. 9%, p = 0.034). ConclusionTKIs demonstrated e cacy and tolerability comparable to real-world data in RR-DTC. PFS was not statistically different between sorafenib and lenvatinib. Our study will help guide physicians in making informed decisions regarding treatment sequencing with TKIs in these patients.

show abstract

Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective

Cited by 4 publications

References 82 publications

NTRK-fusion detection in thyroid and salivary gland cancer offers a targeted therapy with NTRK-inhibitor

NTRK-fusion detection in thyroid and salivary gland cancer offers a targeted therapy with NTRK-inhibitor

Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease

Ten years’ real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer

Contact Info

Product

Resources

About